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ABSTRACT
Over the past 20 years, the prognosis of HER2-positive
breast cancer has been transformed by the
development of anti-HER2 targeted therapies. In early
clinical trials of trastuzumab (ie, the first anti-HER2
agent to be developed) cardiotoxicity became a major
concern. In the first published phase 3 trial of
trastuzumab, 27% of patients receiving anthracyclines
and trastuzumab experienced cardiac events and 16%
suffered from severe congestive heart failure. In
subsequent trials conducted in advanced and early
settings, the incidence of cardiac events was reduced
through changes in chemotherapy regimens, more
strict patient selection and close cardiac assessment.
However, cardiotoxicity remains a significant problem
in clinical practice that is likely to increase as new
agents are approved and exposure times increase
through improved patients’ survival. Though numerous
trials have led to improved understanding of many
aspects of anti-HER2 therapy-related cardiotoxicity, its
underlying physiopathology mechanisms are not well
understood. The purpose of this article is to provide an
in-depth review on anti-HER2 therapy-related
cardiotoxicity, including data on both trastuzumab and
the recently developed anti-HER2 targeted agents.
INTRODUCTION
Breast cancer is the most common type of
cancer among women as well as the first
cause of cancer-specific mortality for women
worldwide.1 It is, however, not a single disease
but rather several distinct diseases that arise
from the same organ.2 Among the currently
identified subtypes, HER2-positive (HER2+)
disease has been the focus of particularly
intense and productive research in the past
20 years. Representing up to 20% of the total
cases, HER2+ disease was traditionally consid-
ered a subtype with poor prognosis, a situation
that has changed by the development of
anti-HER2 targeted therapies (table 1).3 4
HER2 is part of the ErbB family of trans-
membrane growth factor receptor tyrosine
kinases (that also includes HER3 and epider-
mal growth factor receptor (EGFR) among
others). These proteins can be activated inde-
pendently from ligands via homodimerisation
or heterodimerisation (with HER3) or
through neuregulin-1 (NRG-1), a panHER
ligand that plays a significant role in multiple
physiological and pathological processes.5
HER2+ tumour cells possess a highly prolif-
erative phenotype, with increased capacity to
invade, disseminate and stimulate angiogen-
esis.6 The success of trastuzumab in counter-
ing this aggressive behaviour has been,
however, not total, with some patients either
recurring after adjuvant trastuzumab in the
early setting, or proving primary or second-
ary resistant to trastuzumab in the metastatic
setting. This resistance can originate from
multiple causes, such as alterations to the
conformation of the extracellular domain, or
autoactivation of intracellular downstream
signalling pathways.7 8 To circumvent this, a
new generation of anti-HER2 agents has
been developed, each with unique mechan-
isms of action. Among these compounds
several are already in clinical use or in phase
3 studies, while other agents still in earlier
stages of development.9
Besides its usefulness during the process of
neoplastic progression, just as any of the
receptors and pathways that tumour cells
exploit, HER2 plays physiological roles that
are reflected in the toxicity profile of
anti-HER2 agents. In mutated mice without
HER2 expression, no embryos reached full
development and all had cardiac malforma-
tions (such as lack of trabeculae in the myo-
cardium) among other important lethal
organic dysfunctions.10 In another murine
model, genetically engineered mice lacking
HER2 expression exclusively in the heart
developed features of dilated cardiomyop-
athy, with left ventricular chamber dilation,
wall thinning and reduced contractility.11
Additionally, these mice were more suscep-
tible to anthracycline cardiotoxicity. In a
similar study, mice had increased apoptosis
of ventricular cells, and cardiac dysfunction
was reversed through suppression of apop-
tosis.12 In models of cardiac lesions (ischae-
mia, viral and dilated cardiomyopathies),
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cardiac performance was improved and survival ex-
tended by the infusion of recombinant NRG-1 receptor-
active peptide (rhNRG-1).13 Taken together, these data
point towards a fundamental role for HER2 signalling in
heart development during embryogenesis and in cardio-
myocyte survival especially in situations of stress,
through the promotion of survival pathways that inhibit
apoptosis and maintain cardiac function. Thus, cardio-
toxicity is the main concern during anti-HER2 therapy,
as clinical trials with trastuzumab have pointed out.4
In this review, we will explore the state-of-the-art on
anti-HER2 therapy-related cardiotoxicity, starting with




Trastuzumab is a monoclonal antibody that binds to
the extracellular domain of HER2. Its mechanisms of
action include activation of antibody-dependent cytotox-
icity, inhibition of signal transduction, inhibition of
neoangiogenesis and inhibition of repair of DNA damage
caused by the treatment.14 Trastuzumab is approved by
the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for HER2+ patients
with breast cancer in the adjuvant, neoadjuvant and
metastatic settings (table 1).
Cardiotoxicity is the only significant toxicity that tras-
tuzumab treatment entails. From a clinical stand point,
it manifests most often as an asymptomatic drop in
left ventricular ejection fraction (LVEF) or, infrequently,
as congestive heart failure (CHF).15 Remarkably,
although a plethora of studies have revealed much
about its clinical course, risk factors and incidence in
different settings, much remains unknown regarding its
pathophysiology.16 Available research suggests that trastu-
zumab affects the heart in multiple ways:
A. Blocking NRG-1-mediated activation of HER2
reduces fundamental intracellular mechanisms that
allow cardiomyocytes to adequately carry out their
highly specialised function (repetitive contraction).
Affected mechanisms include the ability to maintain
the structure and function of sarcomeres and scaven-
ging of proapoptotic oxidative subproducts of ATP
production in a cell that has high and constant ATP
demands;17 18
B. Trastuzumab binding leads to the downregulation of
the antiapoptotic protein BCL-XL and to the upregu-
lation of the proapoptotic protein BCL-XS.19 The
ratio between antiapoptotic and proapoptotic stimuli
is also a key regulator of mitochondrial function;
C. Oxidative stress leads to the upregulation of angio-
tensin II. Angiotensin II is an inhibitor of NRG-1 that
prevents its binding to other ErbB family receptors to
compensate for HER2 blockade, leading to even
more inhibition of the pathway, and thus to more
oxidative stress forming a cytotoxic vicious cycle. It
also activates NADPH oxidase leading to mitochon-
drial dysfunction and cell death. Furthermore, angio-
tensin II also induces apoptosis through the AT1
receptor.20 21
Twenty years of clinical experience, based on a set of
pivotal phase 2 and 3 trials with trastuzumab have
allowed the construction of a picture of the different
aspects of trastuzumab-related cardiotoxicity. Table 2
summarises the incidence of trastuzumab-associated car-
diotoxicity from the most relevant trials in the meta-
static, neoadjuvant and adjuvant settings.4 22–37
Metastatic setting
In the phase 3 trial that led to the approval of trastuzu-
mab in the metastatic setting, patients with metastatic
breast cancer received either a combination of doxorubi-
cin and cyclophosphamide (AC) or paclitaxel monother-
apy both with or without trastuzumab.4 Thirty-nine
(27.2%) of 143 patients in the AC plus trastuzumab arm
versus 11 (8.1%) of 135 in the AC alone arm and 12
(13.2%) of 91 in the paclitaxel plus trastuzumab arm
versus 1 (1.1%) of 95 in the paclitaxel alone arm experi-
enced CHF. Moreover, a proportionally higher number
of patients who received concomitant anthracycline and
trastuzumab had New York Heart Association (NYHA)
class III and IV CHF when compared with paclitaxel and
trastuzumab (16% vs 2%, respectively). These findings
confirmed what has already been shown in smaller
phase 1 and 2 trials that trastuzumab causes asymptom-
atic drops in LVEF or symptomatic and potentially
deadly (one patient died) CHF.15 The large disparity
between chemotherapy regimens suggests that the con-
comitant association of anthracycline and trastuzumab is
potentially cardiotoxic. From a physiological point of
view, their mechanisms of cardiotoxicity, though differ-
ent, overlap significantly in the formation over oxidative
Table 1 Agents and approval status
Agent Class Status of approval
Trastuzumab Monoclonal antibody Early and advanced disease
Pertuzumab Monoclonal antibody Early (neoadjuvant) and advanced disease
Trastuzumab-emtansine (T-DM1) Drug–antibody conjugate Advanced disease
Lapatinib Tyrosine kinase inhibitor Advanced disease
Afatinib Tyrosine kinase inhibitor Not approved
Neratinib Tyrosine kinase inhibitor Not approved
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Table 2 Trastuzumab-associated cardiotoxicity in clinical trials







Slamon et al (2001)4 MBC first line Phase 3 AC+trastuzumab 143 Not reported 39 (27.2)
AC 135 11 (8.1)
Paclitaxel+trastuzumab 91 12 (13.2)
Paclitaxel 95 1 (1.1)
Marty et al (2005)22 MBC first line Phase 2 Docetaxel+trastuzumab 86 16 (18) 2
Docetaxel 76 7 (8) 0
Gasparini et al (2007)23 MBC first line Phase 2 Paclitaxel+trastuzumab 28 Not reported 0
Paclitaxel 40 Not reported 0
Von Minckwitz et al (2011, 2009)24 38 MBC beyond first line Phase 3 Capecitabine 78 0 0
Capecitabine+trastuzumab 78 1 (1.28) 1 (1.28)
Kaufman et al (2009)25 (Tandem) MBC first line Phase 3 Anastrozole+trastuzumab 103 1 (0.97) 1 (0.97)
Anastrozole 104 0 0
Buzdar et al (2007)26 Neoadjuvant Phase 2 FEC+paclitaxel+trastuzumab (concomitant) 45 Not reported 1
FEC+paclitaxel 19 1 0
Gianni et al (2010)27 Neoadjuvant Phase 3 A+paclitaxel+CMF+trastuzumab 117 30 (27) 2 (1.7)
A+paclitaxel+CMF 217 33 (15) 0
Untch et al (2010)28 (Gepar quattro) Neoadjuvant Phase 3 Chemotherapy+trastuzumab 445 4 (0.89) 1 (0.22)
Chemotherapy 1050 0 2 (0.19)
Buzdar et al (2013)29 Neoadjuvant Phase 3 FEC+paclitaxel+trastuzumab (concomitant) 142 35 (24.6) 1 (0.7)
FEC+paclitaxel+trastuzumab (sequential) 138 21 (15.2) 0
de Azambuja et al (2014)30 (HERA) Adjuvant Phase 3 Chemotherapy+trastuzumab 1 year 1682 120 (7.2) 19 (0.8)
Chemotherapy+trastuzumab 2 years 1673 69 (4.1) 14 (0.8)
Chemotherapy 1744 15 (0.9) 0
Romond et al (2012)31 (NSABP-B31) Adjuvant Phase 3 AC+paclitaxel 743 Not reported 9 (1.2)
AC+paclitaxel+trastuzumab 947 114 (12) 36 (3.8)
Advani et al (2016)32 (N9831) Adjuvant Phase 3 AC+paclitaxel 664 64 (9.6) 6 (0.9)
AC+paclitaxel+trastuzumab 710 119 (16.7) 19 (2.6)
AC+paclitaxel/trastuzumab 570 136 (23.8) 20 (3.5)
Slamon et al (2011, 2015)33 39 Adjuvant Phase 3 AC+docetaxel 1073 114 (11.2) 8 (0.8)
AC+docetaxel+trastuzumab 1074 206 (19.1) 21 (2.0)
Docetaxel+carboplatin+trastuzumab 1075 97 (9.4) 4 (0.4)
Spielman et al (2009)34 Adjuvant Phase 3 FEC/ED 268 7 (2.6) 1 (0.37)
EC/ED+trastuzumab 260 29 (11.1) 4 (1.5)
Joensu et al (2006)35 Adjuvant Phase 3 Docetaxel/vinorelbine+FEC 116 0 2 (1.72)
Docetaxel/vinorelbine+trastuzumab+FEC 115 0 1 (0.86)
Pivot et al (2015)36 Adjuvant Phase 3 Chemotherapy+trastuzumab 6 months 1690 45 (2.7) 9 (0.53)
Chemotherapy+trastuzumab 1 year 1690 70 (4.1) 11 (0.65)
Tolaney et al (2015)37 Adjuvant Phase 2 Paclitaxel+trastuzumab 406 13 (3.2) 2 (0.5)
A, doxorubicin; AC, doxorubicin, cyclophosphamide; CHF, cardiac heart failure; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; EC, epirubicin, cyclophosphamide; ED, epirubicin,






























stress, making increased risk a reasonable hypothesis.40
Recent models of anthracycline toxicity also suggest that
HER2 signalling is essential to protect cardiomyocytes
from it.41
In the pivotal trial, patients who suffered from cardiac
dysfunction mostly were treated with standard cardiac
agents used for CHF, with 75% of patients experiencing
cardiac recovery.4 In this study, older age was the only
significant risk factor associated with cardiotoxicity.4
Other smaller trials also suggested that previous cardio-
vascular disease and hyperlipidaemia are risk factors for
the development of cardiotoxicity.42
Subsequent trials in the metastatic setting, with either
chemotherapy or hormonotherapy showed significantly
less cardiac events as shown in table 2.22–25 This reduc-
tion is explained by a different design of the trials and
eligible population: trastuzumab was not given concomi-
tantly with anthracyclines (though patients could in all
cases have received previous adjuvant anthracyclines
during adjuvant treatment), patients with an LVEF of
<50% were excluded, and cardiovascular follow-up
during study treatment included clinical examinations
and serial cardiac assessment, mostly echocardiography.
It is important to note that the initial results of trastuzu-
mab impacted on the development of all anti-HER2
agents, the selected population in clinical trials does not
always represent patients with HER2+ metastatic breast
cancer treated in daily clinical practice. As shown in
large cohort studies conducted in an unselected popula-
tion, the risk of cardiotoxicity with the use of trastuzumab
seems to be higher. Thus, it is likely that in daily clinical
practice, the reported cardiotoxicity is higher than in
trials as reported in some cohorts of patients.43 44 In the
meta-analysis of randomised trials versus cohort studies
conducted by Mantarro et al,43 cohort studies consistently
reported higher cardiotoxicity rates than randomised
trials in the metastatic setting: 4.4% vs 2.8%, respectively.
Neoadjuvant setting
The neoadjuvant strategy has been explored extensively
in HER2+ disease.45 The academic debate has been
centred from an early point on the issue of associating
anthracyclines and trastuzumab concomitantly versus
sequentially and the need to balance potential benefits
(ie, higher pathological complete response rate) with
potential risks (ie, higher cardiotoxicity).46 In the
seminal trial by Buzdar and colleagues, 45 women
received fluorouracil, epirubicin, cyclophosphamide
(FEC) and trastuzumab followed by paclitaxel and trastu-
zumab. A total of 19 women in the control group
received only FEC followed by paclitaxel. The results of
the trial suggested for the first time that concurrent
administration of anthracycline and trastuzumab was
safe (only one patient developed CHF) and yielded
increased benefits (response rates were also significantly
higher in the combination arm), putting into question
the conclusions taken from the initial experience with
metastatic disease.26
Subsequently, the larger NeOAdjuvant Herceptin
(NOAH) trial further investigated the safety of combin-
ing anthracyclines with trastuzumab concomitantly. Of
the 117 patients who received combined therapy, 27%
suffered LVEF drops (grades 2–3) and 1.7% had symp-
tomatic CHF versus 15% and 0%, respectively, in the
non-trastuzumab group (215 patients).27 Similarly, in the
geparQUATTRO trial with 1495 patients, only 4 had
LVEF drops and 2 CHF in the three groups that received
combined therapy.28 Although a combined analysis of
these three neoadjuvant trials showed that the trastuzu-
mab regimens where more cardiotoxic than the non-
trastuzumab (significant increase in the rate of cardio-
toxicity (OR 1.95, 95% CI 1.16 to 3.29, p=0.36)),47 none
of these trials had a design capable of resolving the crit-
ical question of the cardiac safety of concurrent treat-
ment with anthracycline and trastuzumab.
The ACOSOG Z1401 was designed to answer this ques-
tion with a total of 280 patients randomised between two
trastuzumab containing regimens, one with concomitant
anthracycline and one with trastuzumab after anthracy-
cline. The dose of epirubicin in the FEC regimen was
75 mg/m2. The combination arm had a non-significantly
higher number of LVEF drops and CHF (24.6% and
0.7%, respectively) as compared with the sequential
group (15.2% and 0%, respectively). The response rate
was the same in the two treatment arms.29 Therefore,
given the data presented above, it is generally recom-
mended not to combine trastuzumab with anthracy-
clines in the curative setting, as well as in the metastatic
setting, due to increased risk of cardiac events.
Adjuvant setting
The large adjuvant randomised phase 3 trials, with
higher number of patients and predefined close cardiac
follow-up, provided the most detailed and extensive infor-
mation on trastuzumab-related cardiotoxicity (table 2).
Specific cardiotoxicity analyses with long-term follow-up
have been published for most of these trials.30–32
In the herceptin adjuvant (HERA) trial, 5102 patients
were randomised to observation or trastuzumab for 1 or
2 years.48 Cardiac assessment included LVEF assessment
by either echocardiogram or multiple gated acquisition
scintigraphy (MUGA) in predefined time points. After a
median follow-up of 8 years, the study confirmed that
the incidence of trastuzumab-associated toxicity
remained low, that most cases of cardiac events occurred
during trastuzumab use and that the majority were
reversible after the interruption of trastuzumab.30 The
incidence of LVEF decline was 0.9%, 4.1% and 7.2% in
the observation, 1-year and 2-year trastuzumab arms,
respectively. The observed incidence of CHF remained
very low (0% in the observation arm and 0.8% in the
1-year and 2-year trastuzumab arms). It is important to
note that the very low risk of cardiotoxicity is likely con-
nected to patient selection and study design. The 2-year
arm suffered more LVEF drops than the 1-year arm, sug-
gesting that time of exposure plays a role in the risk of
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developing this side effect. Since there was no added
clinical benefit for the 2-year arm, 1 year of trastuzumab
remains the standard of care in the adjuvant setting. In
the metastatic setting, however, considering the longer
exposure times that are likely to issue from recently
introduced regimens exposure times to trastuzumab may
go beyond 2 years.49–51 Registries are currently in pro-
gress to better elucidate the safety of prolonged expos-
ure to anti-HER2 targeted agents in the clinical practice
setting.52 Other adjuvant trials showed a similar low
number of cardiac events (table 2); however, selection
criteria, cardiac follow-up and definitions of cardiac
events varied across the studies, making direct compari-
sons difficult. Recently published long-term follow-up
data (median follow-up 9.2 years) of the B31 trial
showed that only 6 (0.9%) and 19 (2.6%) patients in the
control arm and experimental arm, respectively, experi-
enced CHF. An analysis for risk factors was conducted:
60 years or older, baseline LVEF between 50% and
54.9% (a group that was excluded from HERA by
design) or 55% and 64.9%, use of antihypertensive med-
ications proved to be significantly associated with
increased risk of cardiotoxicity. Interestingly, the use of
radiation therapy and BMI were not associated with sig-
nificant increased risk in this trial, nor in the N9831
study.32 It is also important to note that the nature of
cardiac vigilance during the study treatment varied
widely between studies. For example, in the N9831 trial,
LVEF assessment was maintained for 21 months at most,
except in cases where there was a suspicion of cardiac
toxicity, while in the HERA study cardiac assessment was
mandated for 10 years.30 LVEF drops occurred in 15.4%
of patients in the control arm (AC+paclitaxel), 31.1% in
the sequential (AC+paclitaxel followed by trastuzumab)
arm and 27.1% in the concomitant arm (AC+paclitaxel/
trastuzumab; table 2). CHF grades 2–4 were respectively
0.3%, 2.8% and 3.3%.53 Long-term data of the same
trial revealed a stably low 6-year incidence of cardiac
events. In this trial, as in the HERA and B31 trials, most
events happened during treatment and were reversed
quickly when treatment was interrupted and cardiac
intervention established.
Recently, the BCIRG 006 trial presented the 10-year
results. This is the only trial testing a non-anthracycline
regimen (TCH). Cardiac events were lower in the TCH
arm compared with AC-TH (0.4% vs 2%, respectively).
A recently published meta-analysis of all the adjuvant
trials, with a total of 18 111 patients concluded that
adjuvant therapy with trastuzumab significantly increases
the risk of grades 3 and 4 CHF (RR 3.04 (95% CI 1.12
to 7.85; p<0.00001)).54
Pertuzumab
Pertuzumab is a monoclonal antibody that acts by
binding to domain II of HER2 receptor with consequent
inhibition of HER2–HER3 heterodimerisation.55 It has
been recently approved for clinical use (table 1) in com-
bination with trastuzumab and chemotherapy as
neoadjuvant therapy and first-line therapy in patients
with HER2+ metastatic breast cancer.56
One early phase 2 study of the combination suggested
increased cardiotoxicity, leading to early interruption
of pertuzumab.57 Improved patient selection (exclusion
of high-risk groups such as patient who had a history of
trastuzumab-related cardiotoxicity) and cardiac assess-
ment, led to a reduction in events during subsequent
studies.58–61 In a large pooled analysis, Lenihan and col-
leagues evaluated the pertuzumab cardiac safety data.
Overall, out of 598 patients included in the analysis, 35
(5.9%) developed asymptomatic left ventricular systolic
dysfunction (LVSD), defined as a decrease from baseline
in LVEF of ≥10 points to a value of <50% at any postba-
seline LVEF assessment) and 4 (0.7%) patients devel-
oped symptomatic CHF.62
The main evidence supporting the cardiac safety of
the trastuzumab–pertuzumab combination comes from
the CLEOPATRA phase 3 trial in metastatic patients
(table 3). The incidence of adverse cardiac events of any
grade was 16.4% in the placebo arm and 14.5% in the
pertuzumab arm.63 LVSD of any grade was the most fre-
quently reported cardiac event (8.3% in the placebo
arm vs 4.4% in the pertuzumab arm).63 Few cases of
CHF were reported, 7 (1.8%) in the placebo arm and 4
(1.0%) in the pertuzumab arm.63 Prior exposure to
anthracyclines and prior radiotherapy were identified as
potentially important risk factors irrespective of treat-
ment arm.63 Interestingly prior exposure to trastuzumab
was not significantly associated with the development of
LVSD,63 but only 10% of the study population was previ-
ously exposed in the early setting to anti-HER2 targeted
therapy. Overall, the cardiotoxicity profile of the com-
bination was favourable: adverse cardiac events were
largely reversible and clinically manageable.63 Two
studies of pertuzumab-based therapy in the neoadjuvant
setting (ie, NeoSphere and TRYPHAENA) showed a
similar low incidence of cardiac events.64 65 Hence, the
available data coming from the neoadjuvant and meta-
static settings do not suggest dual anti-HER2 blockade
with trastuzumab and pertuzumab increases the inci-
dence of cardiac events. This was also confirmed by a
meta-analysis combining the cardiotoxicity data from the
CLEOPATRA and NeoSphere studies: as compared with
trastuzumab alone, the addition of pertuzumab was not
associated with an increased risk of LVEF drops (OR
0.66, p=0.19).66 No published data are available so far
on the use of pertuzumab in the adjuvant setting; the
results of the APHINITY trial (NCT01358877) will give




Trastuzumab-emtansine (T-DM1) is an antibody drug
conjugate composed of a monoclonal antibody (ie, trastu-
zumab) connected to a potent cytotoxic antimicrotubule
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agent (ie, emtansine or DM1).76 This formulation has
been recently approved for the treatment of patients
with HER2+ metastatic breast cancer previously exposed
to taxane and trastuzumab (table 1).
All the published phase 2 studies available showed
a favourable cardiotoxicity profile with the use of
T-DM1.77–81 Most of these studies were conducted in
patients with metastatic breast cancer beyond first-line
therapy: hence, the majority of them had prior exposure
to trastuzumab. Nevertheless, the risk of developing a
cardiac event with the use of this compound is low, as also
confirmed by the available phase 3 studies67 82 (table 3).
In the EMILIA trial,67 T-DM1 was compared with lapa-
tinib plus capecitabine in 991 patients with HER2+ meta-
static breast cancer. Only three patients in each arm had
a decrease in LVEF from baseline to <40%.67 A total of
eight patients (1.7%) in the T-DM1 arm and 7 (1.6%) in
the lapatinib plus capecitabine arm had a LVEF reduc-
tion ≥15 points below the baseline value and to <50%.67
Only one patient in the T-DM1 arm developed grade 3
LVSD.67 The TH3RESA trial in a heavily pretreated
population showed similar results.82
In the early setting, two studies with the use of neoad-
juvant T-DM1-based therapy have reported results, but
no cardiotoxicity data were reported.83 84 In the adju-
vant setting, the single-arm phase 2 TDM4874g
(BO22857) trial investigated the cardiac safety and
overall feasibility of T-DM1 for ∼1 year after prior expos-
ure to anthracycline-based chemotherapy in the (neo)
adjuvant setting.68 Patients received 4 cycles of (neo)
adjuvant AC or 3–4 cycles of FEC followed by 4 cycles of
T-DM1; then, patients could have received an optional
3–4 cycles of docetaxel with or without trastuzumab, and
finally all patients continued T-DM1 for a planned 17
Table 3 Cardiotoxicity in the main phase 3 clinical trials with the use of anti-HER2 targeted agents other than trastuzumab









Swain et al49 MBC, first-line Docetaxel+trastuzumab
+placebo
396 27 (6.6) 13 (3.3)
Docetaxel+trastuzumab
+pertuzumab
408 27 (6.6) 6 (1.5)
T-DM1
Verma et al67 MBC, first-line and
beyond first-line
T-DM1 495 8 (1.7) 1 (0.2)
Lapatinib+capecitabine 496 7 (1.6) 0 (0.0)
Krop et al68 MBC, beyond first-line T-DM1 404 6 (1.0) 0 (0.0)
Treatment of physician’s
choice




MBC, beyond first-line Lapatinib+capecitabine 163 4 (2.5) 0 (0.0)
Capecitabine 161 4 (2.5) 0 (0.0)
de Azambuja et al71 Neoadjuvant setting Lapatinib+paclitaxel 154 2 (1.3) 1 (0.6)
Trastuzumab+paclitaxel 149 2 (1.3) 0 (0.0)
Lapatinib+trastuzumab
+paclitaxel
152 7 (4.6) 2 (1.3)
Piccart-
Gebhart et al72
Adjuvant setting CT+trastuzumab 2097 97 (4.6) 53 (2.5)
CT+lapatinib 2100 63 (3.0) 37 (1.8)
CT+trastuzumab →
lapatinib
2091 57 (2.7) 37 (1.8)
CT+trastuzumab
+lapatinib
2093 103 (4.9) 68 (3.2)
Neratinib and afatinib
Harbeck et al73 MBC, first-line and
beyond first-line
Afatinib+vinorelbine 332 1 (0.3) 0 (0.0)
Trastuzumab+vinorelbine 168 3 (1.8) 2 (1.2)








Chan et al75 Adjuvant setting Neratinib 1420 4 (0.3) 1 (0.1)
Placebo 1420 2 (0.1) 0 (0.0)
*Defined as CHF, decreased LVEF, LVSD and peripheral oedema.
CHF, cardiac heart failure; CT, chemotherapy; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; MBC,
metastatic breast cancer; T-DM1, trastuzumab-emtansine.
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cycles of HER2-directed therapy.68 A total of 153 patients
were randomised: no symptomatic CHF were reported
and mean LVEF was stable throughout T-DM1 treat-
ment.68 A total of four patients (2.6%) experienced a
LVEF decline ≥10 points below the baseline value and
to <50%, and one of these women discontinued T-DM1
with an LVEF of 45%.68 Two of four LVEF declines
occurred during treatment with optional docetaxel
plus trastuzumab.68 Ongoing studies in this setting (eg,
the KATHERINE (NCT01772472), the KAITLIN
(NCT01966471) and the ATEMPT (NCT01853748)
trials) are awaited to better define the safety profile of
long-term exposure to T-DM1.
TIROSINE KINASE INHIBITORS
Lapatinib
Lapatinib is a FDA and EMA approved dual tyrosine
kinase inhibitor (TKI) of EGFR and HER2 available for
patients with advanced disease (table 1).85 Lapatinib acti-
vates the AMP-kinase pathway which increases ATP reserves
and induces a metabolic stress response in human cardio-
myocytes that may protect against TNF-α-induced cell
death.86 Hence, preclinical evidence suggested that lapati-
nib may ultimately protect the heart against the cardiotoxi-
city induced by anti-HER2 targeted agents.86 Table 3 show
the most relevant phase 3 studies for lapatinib.
In the registration phase 3 study, 324 patients with
HER2+ metastatic breast cancer progressing after anthra-
cycline, taxane and trastuzumab were randomly allo-
cated to receive lapatinib combined with capecitabine or
capecitabine alone.87 In the study, lapatinib showed a
favourable cardiotoxicity profile. Overall, 11 patients
developed 12 events.70 A total of 11 patients experi-
enced 12 events of LVEF drop; 4 patients in each arm,
developed grade ≥3 LVSD or ≥20 points absolute
decrease in LVEF from the baseline value, but all these
episodes were reported as asymptomatic.70 The patients
with LVEF drop were previously exposed to cardiotoxic
agents (anthracyclines and trastuzumab) and/or had
other cardiac risk factors (ie, hypertension, left chest
radiation and cardiopulmonary diseases).70
Following the results of this study, several other phase
3 randomised trials evaluated the efficacy and safety of
lapatinib as single-agent or combined with chemother-
apy, endocrine therapy or trastuzumab in the treatment
of patients with HER2+ metastatic breast cancer.87–92
Overall, these studies confirmed the low risk of cardio-
toxicity with lapatinib; however, the definition of cardiac
events used in these studies was not homogeneous and
thus a clear comparison with other results becomes
more difficult.
A large combined analysis conducted by Perez et al93
investigated the cardiotoxicity profile of lapatinib in 3689
patients treated with the TKI as monotherapy (54%) or
in combination (41% with chemotherapy or endocrine
therapy, and 5% with trastuzumab). This large analysis
confirmed the low incidence of cardiac events (1.6%)
with a high rate of demonstrated reversibility of LVEF
(88%) with the use of lapatinib. It is, however, important
to note that only a small part of the patient population
(14.9%) had previously received anthracyclines.93
In the neoadjuvant and adjuvant settings, all phase 3
trials confirmed the safety of the combined treatment of
lapatinib–trastuzumab and of lapatinib alone.71 72 94–96
In the NeoALTTO study there were three arms: trastuzu-
mab alone, lapatinib alone and the combination of
trastuzumab and lapatinib were compared in the neoad-
juvant setting; a low incidence of primary cardiac events
was observed in all treatment arms (<1%) although
there were more primary and secondary cardiac events
in the combined arm (7, 5%) than in either the lapati-
nib arm (2, 1%) or the trastuzumab arm (2, 1%). No
significant difference for primary or secondary cardiac
events was observed between the three treatment
arms.71 96 In the ALTTO trial, 8381 patients with centrally
confirmed HER2+ early-stage breast cancer were ran-
domly assigned to 1 year of adjuvant anti-HER2 targeted
therapy with trastuzumab, lapatinib, their sequence (tras-
tuzumab followed by lapatinib) or their combination
(trastuzumab plus lapatinib). Cardiac events were defined
in the protocol as in the NeoALTTO study.71 The inci-
dence of primary and secondary cardiac events was low in
all the treatment arms. Between 0.25% and 0.97% of
patients developed primary cardiac end points with three
fatal cardiac events in the sequential arm and one in
each of the other treatment arms.72 These studies
support the cardiac safety of lapatinib both as single
anti-HER2 agent and as dual anti-HER2 blockade in com-
bination with trastuzumab. As shown in the meta-analysis
by Valachis et al,66 the combination of lapatinib and tras-
tuzumab seems not to be associated with an increased
risk of developing CHF nor LVEF drops (CHF OR 0.64;
p=0.42 and LVEF OR 0.53; p=0.54).
Afatinib and neratinib
Neratinib and afatinib are novel next-generation TKIs
targeting EGFR, HER2 and HER4.85 They are not yet
approved for use in breast cancer (table 1). In the meta-
static setting, several phase 2 trials evaluated the activity
of neratinib and afatinib either as monotherapy or in
combination with chemotherapy (neratinib in combin-
ation with paclitaxel or capecitabine, afatinib in combin-
ation with vinorelbine) or endocrine therapy (afatinib in
combination with letrozole). Overall, the cardiotoxicity
profile of these compounds showed to be favourable as
demonstrated in the phase 3 studies (NEfERT-T and
LUX-Breast 1) in the metastatic and early (ExteNET)
settings73 74 (table 3). The only phase 3 trial exploring
the use of neratinib in the adjuvant setting reported a
low rate of cardiac events (table 3).
ELDERLY POPULATIONS
Elderly patients (more than 70 years old) benefit from
adjuvant treatment, although to a lesser extent than
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younger patients due to issues of comorbidity, function-
ality and life expectancy.97 However, it is clear that well-
selected patients can safely receive and benefit from
adjuvant therapy.98 99 Data for use of trastuzumab in the
elderly populations are limited, since most studies
placed age limitations for inclusion.100 The available
data from phase 3 trials suggested higher risk of cardio-
toxicity (both in B31 and N9831) in patients above
60 years of age.31 32 101 Although there are few trials spe-
cifically studying the use of trastuzumab in the elderly
populations, observational studies suggest high treat-
ment completion rates.102 103 In the APT phase 2 study
of weekly paclitaxel and trastuzumab, 10.1% of patients
were older than 70. The study showed no significant
increase in cardiac toxicity.37 A cohort study in the elderly
population (median age 71 years) focused specifically on
cardiotoxicity: a total of 9535 patients were included and
2203 (23.1%) received trastuzumab. The CHF rate was
29.4% and 18.9% among patients who received trastuzu-
mab and those that did not, respectively.104
Pertuzumab studies, designed in recent times, are
more likely to have larger elderly populations. In the
landmark CLEOPATRA trial, 127 out of 808 patients
(15.7%) were above 65 years old. The risk of developing
cardiac events did not seem to be significantly higher
(≥65 vs <65 years, HR=1.25; 95% CI 0.61 to 2.56,
p=0.5502) in the elderly population, although the low
number of events limits the reliability of this finding.105
From the cardiotoxicity point of view, the limited avail-
able data support the use of anti-HER2 agents in the
elderly population.
BIOMARKERS
The search and clinical testing of biomarkers for cardio-
toxicity has been a central area for research in
cardio-oncology. An ideal biomarker could help stratify
patients between different risks, thus allowing for more
personalised follow-up regimens during treatment, as
well as early interruption before functional alteration
LVEF is established.106 Several different potential bio-
markers have been studied, including troponins I and T
(TnI and TnT, both markers of myocardial injury),
B-natriuretic peptide (BNP a marker of wall stress), and
C reactive protein (CRP; a marker of inflammation).
Multiple studies dealt with the role of TnI in predict-
ing trastuzumab cardiotoxicity, with discordant results.
The largest study conducted so far investigated the role
of TnI in 251 women receiving trastuzumab therapy. TnI
levels were measured before and after each dose of tras-
tuzumab.107 A total of 42 (17%) patients suffered
cardiac toxicity (LVEF drop or CHF) and the cardiac
events were positively correlated to TnI elevation.
Approximately 60% of these patients recovered, but a
significantly lower number of those who were
TnI-positive recovered as compared with women who
were TnI-negative (35% vs100%, HR 2.88, 95% CI 1.78
to 4.65; p<0.001). Thus, the results of this study suggest
that TnI predicts which patients will not recover. It is,
however, significant to note that 7 of the 36 patients with
elevated TnI had elevated level already at baseline, sug-
gesting that possibly they already had otherwise
undetectable cardiac injuries (from anthracyclines or
other causes). Furthermore, these results are not corro-
borated by other smaller studies (77). A recently pub-
lished study where 214 women were receiving adjuvant
EC followed by docetaxel with or without trastuzumab
(depending on HER2 status) showed no correlation
between trastuzumab and elevated TnI levels (4.2% in
trastuzumab group and 3% in trastuzumab-free group).108
TnT, CRP and BNP have less evidence in favour of
their usefulness as biomarkers. In one study, 54 women
with early-stage HER2+ breast cancer, elevated CRP pre-
dicted decreased LVEF, but no association was found
between LVEF and BNP or TnI.109 Another study testing
eight biomarkers in 78 patients receiving adjuvant trastu-
zumab, found no positive correlation between CRP and
BNP and the risk of cardiotoxicity.110 An exploratory
cardiac substudy within the phase 2 study of first-line
weekly paclitaxel in combination with trastuzumab and
pertuzumab,61 investigated cardiac biomarkers (TnI and
BNP) and speckle-tracking echocardiography (to
measure global longitudinal strain) as adjuncts to LVEF
monitoring for the early detection of treatment-related
cardiotoxicity.111 No changes in global longitudinal
strain were observed during the study. TnI was detect-
able in 3 (4.3%) patients and BNP in 2 (3.0%) but they
were not associated with LVEF decline.111 Looking spe-
cifically at TnT, a small study with only 19 patients sug-
gests that TnT increase predicts LVEF decrease at
15 months.112 Another, larger study (42 patients),
however, found no correlation.113
Another possible strategy in risk stratification is the
use of variations in single nucleotide polymorphisms
(SNPs). Evidence has associated SNPs with enhanced tox-
icity or efficacy in cancer treatments. Small studies suggest
that SNPs in the HER2 gene, namely Pro1170Ala and
Ile655Val, can predict the occurrence of trastuzumab-
associated cardiotoxicity.114 115 However, this deserves
further confirmation before being used in clinical practice.
Currently, there is not enough evidence to recom-
mend routine use of any biomarker, including TnI in
daily practice.116
FUNCTIONAL IMAGING
Functional imaging has a crucial role in identifying
patients at risk of developing adverse cardiac events
when treated with anti-HER2 agents and those experien-
cing cardiac vents while on treatment. The serial meas-
urement of LVEF is the mainstay of cardiac surveillance
in patients under treatment with anti-HER2 agents.
Echocardiography is the most well-established and
widely used technique in the monitoring of cardiac
patients during treatment. Major advantages of this tech-
nique include widely availability, no use of radiation, no
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side effects and the relative low cost.117 Echocardiography
allows volumetric measures, ejection fraction evaluation
and assessment of diastolic heart function. Recent data
suggest that newer echocardiography-derived measures of
myocardial mechanics (ie, strain indices and ventricular–
arterial coupling) can provide additional insights into
cardiac function during cancer treatments and may serve
as a sensitive marker of early myocardial dysfunction.118
MUGA is more accurate than echocardiography in
determining ejection fraction and has an important role
in the surveillance of cardiotoxicity associated with
cancer treatments.119 Nevertheless, MUGA requires the
injection of a radiotracer, which is very expensive and is
not available in all cancer centers.117
Cardiac MR (CMR) is an extremely accurate tech-
nique in determining cardiac volumes and ejection frac-
tion with a potential role in identifying small regions of
scarring and inflammation.117 Recently, CMRI with myo-
cardial strain showed to be a potential useful mean of
detecting trastuzumab-related cardiotoxicity.120 However,
the high cost and lack of availability are likely to limit
the clinical use of this technique.119
CARDIOPROTECTIVE STRATEGIES
A number of pharmacological agents are currently in
use to treat CHF with high-quality evidence of improve-
ments in outcomes (including β-blockers and ACE inhi-
bitors).121 122 As we have seen these standard CHF
treatment agents have been used in patients experien-
cing cardiac events due to trastuzumab-associated cardio-
toxicity, and most patients experience cardiac recovery
with these treatments. This has led to interest in investi-
gating such agents as cardioprotective strategies during
anthracycline and/or trastuzumab treatments. In the
case of anthracycline-associated cardiotoxicity, few small
studies suggest that this strategy may be useful.123 124
This has led to the design of randomised trials exploring
this pharmacological strategy, including two recently
reported trials—MANTICORE and PRADA.
MANTICORE is a randomised trial of perindopril
(ACE inhibitor) in comparison to bisoprolol (β-blocker)
and placebo in patients who are to start adjuvant trastu-
zumab. The planning accrual was 153 patients, but this
trial was interrupted early (99 patients) due to the evident
superiority of one of the strategies. In this trial, bisoprolol
significantly prevented reduction in LVEF and trastuzumab
treatment interruptions when compared with perindopril
or placebo (p value of <0.001). No significant change was
detected in left ventricular remodelling (a possible early
marker of trastuzumab cardiotoxicity).125
In the PRADA study candesartan (an angiotensin
receptor blocker) and metoprolol were compared in
combination or alone against placebo in 130 early breast
cancer treated patients with adjuvant anthracyclines and
trastuzumab. Study treatment was started before chemo-
therapy with FEC and only 22.2% of patients received
trastuzumab. The overall decline of LVEF in the placebo
group was 2.6% (95% CI 1.5% to 3.8%) and 0.8% (95%
CI 20.4% to 1.9%) in the candesartan group (p=0.026).
Combination or metoprolol alone did not show signifi-
cant benefit. This result suggests that candesartan may
reduce the incidence of LVEF drops.126
Though the results of MANTICORE and PRADA are
interesting, it is very important to bear in mind that both
studies are small in size and exclude patients with cardiac
comorbidities, and therefore their results are not at the
moment a solid basis for clinical decision-making and
should be further explored in larger studies.
CONCLUSIONS
Cardiotoxicity remains a clinically significant toxicity of
anti-HER2 therapies. Novel agents seem to have a
reduced potential for cardiotoxicity. However, the find-
ings from clinical trials should be considered in the
context of the patient selection criteria: the eligible
population in these studies (ie, younger age, higher
LVEF at baseline and less cardiovascular comorbidities)
do not always fit with average patients in clinical prac-
tice. Further analysis of data is also made more difficult
by the myriad of different criteria used to define cardiac
events in each study, as well as the different follow-up
plans during and after study treatments. Therefore, a
common definition on cardiac events should be applied
in future clinical trials.
In practice, longer periods of combined treatment,
more lines of therapies and longer survival is likely to
increase the relevance of cardiotoxicity in the context of
metastatic disease. The data available to be applied in
clinical practice are almost exclusively derived from tras-
tuzumab trials, and can provide some guidance on some
risk factors that can help in deciding the chemotherapy
choice and cardiac assessment during treatment.
Importantly, at the first suspicion of cardiac toxicity,
patients should have a cardiac assessment because of its
high proportion of reversibility with anti-HER2 interrup-
tion and proper cardiac intervention. Unfortunately, at
this moment, there is no validated biomarker or any
other means of selecting patients who need less exhaust-
ive cardiac follow-up or less cardiotoxic chemotherapy
regimens, with the exception of clinical cardiac risks
(eg, hypertension, obesity, etc).
Guidelines and position papers by the European
Society for Medical Oncology (ESMO), the European
Society of Cardiology (ESC) and the American Society
of Clinical Oncology (ASCO) address the issue of
trastuzumab-associated cardiotoxicity.127–129 These guide-
lines highlight the importance of patient selection, treat-
ment of potential risk factors for increased cardiotoxicity
and of adequate cardiac assessment during treatment. It
is important to note, however, that no studies showed that
such methods may change cardiac outcomes.130 The
recently published ASCO guidelines on treatment of
HER2+ early disease suggests the use of trastuzumab, car-
boplatin and docetaxel in patients considered to be at
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high risk for cardiotoxicity as a reasonable approach.129
As more data from new studies with pertuzumab and
T-DM1 become available, further insights into this phe-
nomenon will probably be available.
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